Syros Pharmaceuticals Stock Price. Everything You Need To Know About The Syros Pharmaceuticals Stock!

Syros Pharmaceuticals, Inc. is a Massachusetts-based company that focuses on the development of gene control therapies for cancer and diseases. The company currently employs 117 full-time employees and went public on June 30, 2016.

The company is dedicated to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101. Tamibarotene is a selective retinoic acid receptor alpha (RARα) agonist for RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Meanwhile, SY-2101 is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL).

Syros Pharmaceuticals, Inc.’s product candidate also includes SY-5609, a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) being developed for patients with select solid tumors and in combination with gemcitabine and with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. The company is also focused on the development of multiple preclinical programs in oncology.

It’s important to note that investing in stocks carries a level of risk. Therefore, it’s crucial to conduct thorough research and seek professional advice before making any investment decisions. To stay up-to-date with the latest developments in the industry, it is vital to research this stock regularly, including its stock price today, shares, and market cap. While Syros Pharmaceuticals, Inc. specializes in the development of gene control therapies for cancer and diseases, it’s essential to approach any investment decision with caution and careful consideration.